| Medical and Health Sciences | 2021-2025 | 364 | SA 2 | 99.92 |
| Biological Sciences | 2021-2025 | 289 | SA 4 | 99.71 |
| Infectious Diseases | Lifetime | 406 | SA 2 | 98.53 |
| Infectious Diseases | 2021-2025 | 10 | SA 1 | 99.83 |
| Epidemiology | 2021-2025 | 251 | SA 1 | 98.05 |
| Virology | 2021-2025 | 18 | SA 1 | 95.64 |
| Molecular Biology | 2021-2025 | 922 | SA 2 | 94.83 |
| Applied Microbiology and Biotechnology | 2021-2025 | 37 | SA 1 | 93.12 |
| Public, Environmental and Occupational Health | 2021-2025 | 943 | SA 8 | 90.34 |
| COVID-19 Clinical Research Studies | Lifetime | 108 | SA 4 | 99.34 |
| SARS-CoV-2 and COVID-19 Research | Lifetime | 157 | SA 4 | 99.29 |
| Long-Term Effects of COVID-19 | Lifetime | 97 | SA 4 | 98.87 |
| SARS-CoV-2 detection and testing | Lifetime | 230 | SA 4 | 95.88 |
| COVID-19 diagnosis using AI | Lifetime | 253 | SA 13 | 95.44 |
| COVID-19 epidemiological studies | Lifetime | 721 | SA 13 | 95.68 |
| Antibiotic Use and Resistance | Lifetime | 855 | SA 3 | 95.31 |
| Poxvirus research and outbreaks | Lifetime | 454 | SA 2 | 92.29 |
| COVID-19 Clinical Research Studies | 2021-2025 | 18 | SA 1 | 99.81 |
| Long-Term Effects of COVID-19 | 2021-2025 | 21 | SA 1 | 99.54 |
| SARS-CoV-2 and COVID-19 Research | 2021-2025 | 38 | SA 1 | 99.73 |
| Poxvirus research and outbreaks | 2021-2025 | 6 | SA 1 | 98.56 |
| Antibiotic Use and Resistance | 2021-2025 | 80 | SA 1 | 97.76 |
| Bacillus and Francisella bacterial research | 2021-2025 | 38 | SA 4 | 95.12 |
| Antibiotic Resistance in Bacteria | 2021-2025 | 260 | SA 4 | 96.71 |
| SARS-CoV-2 detection and testing | 2021-2025 | 215 | SA 1 | 95.31 |
| vaccines and immunoinformatics approaches | 2021-2025 | 106 | SA 8 | 94.28 |
| Viral Infections and Vectors | 2021-2025 | 412 | SA 2 | 93.87 |
| Animal Virus Infections Studies | 2021-2025 | 338 | SA 2 | 92.18 |
| COVID-19 diagnosis using AI | 2021-2025 | 305 | SA 28 | 93.33 |
| Tuberculosis Research and Epidemiology | 2021-2025 | 501 | SA 1 | 93.40 |
| Viral gastroenteritis research and epidemiology | 2021-2025 | 847 | SA 3 | 89.18 |
| Herpesvirus Infections and Treatments | 2021-2025 | 353 | SA 4 | 87.57 |
| Antifungal resistance and susceptibility | 2021-2025 | 581 | SA 2 | 89.46 |
| Fungal Infections and Studies | 2021-2025 | 599 | SA 1 | 86.30 |
| Bacterial Identification and Susceptibility Testing | 2021-2025 | 877 | SA 8 | 81.13 |
| Infection Control and Ventilation | 2021-2025 | 589 | SA 2 | 81.06 |
| Antimicrobial Resistance in Staphylococcus | 2021-2025 | 876 | SA 6 | 80.53 |
| Nosocomial Infections in ICU | 2021-2025 | 564 | SA 7 | 75.63 |
| Cancer therapeutics and mechanisms | 2021-2025 | 751 | SA 38 | 75.75 |
| Hepatitis Viruses Studies and Epidemiology | 2021-2025 | 453 | SA 3 | 77.14 |
| Nail Diseases and Treatments | 2021-2025 | 928 | SA 5 | 69.21 |
| Transgenic Plants and Applications | 2021-2025 | 726 | SA 18 | 57.66 |
| Infection Control in Healthcare | 2021-2025 | 971 | SA 8 | 38.85 |
